AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA)
Go back to AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA)| AbbVie (NYSE: ABBV) | Delayed: 255.00 +4.09 (1.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $250.91 | 52 Week High | $68.12 | |||
| Open | $251.23 | 52 Week Low | $50.71 | |||
| Day High | $255.31 | P/E | 55.31 | |||
| Day Low | $249.74 | EPS | $4.61 | |||
| Volume | 4,397,557 | |||||
